title: Macular auto-fluorescence is a follow-up parameter for cystoids macular edema.
abstract: This study aimed to evaluate if macular autofluorescence (MAF) is a valuable, non-invasive follow-up parameter for cystoid macular edema. A total of 71 eyes (71 cases) with cystoid macular edema (CME) were included in the study. Macular pigment (MP) was evaluated using HRA2 (infrared) IF and FA models. The density of MP was graded into three categories: without, partial, and normal amount of MP. A comparison was made between the baseline (before the first administration) level and at the fourth month, following three consecutive intravitreal lucentis injections every month. The morphology and distribution of MAF, and the density and distribution of MP were regarded as the main outcome measures. At the baseline visit, all eyes with CME had petaloid/irregular-shaped MAF in the macular area (100%). No MAF was detected in the control eyes (0). There was significant difference in MAF between the CME and normal groups (P=0.000). At the fourth monthly visit, normal levels of MP density without MAF was detected in 68 eyes (95.8%) with the best corrected spectacular visual acuity increasing to at least 1 line accordingly. We conclude that macular MAF can be used as a follow-up parameter for patients with CME. MP and MAF can indirectly reflect the fovea cone function.
authors.affiliation: Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Tongren Hospital, Capital Medical University, Beijing, 100730, China, zhangxy1@trhos.com.
authors.forename: XinYuan
authors.initials: X
authors.lastname: Zhang
authors.forename: XiaoHong
authors.initials: X
authors.lastname: Gong
authors.forename: YanHong
authors.initials: Y
authors.lastname: Wang
authors.forename: NingLi
authors.initials: N
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005451:Fluorescein Angiography; D005453:Fluorescence; D006801:Humans; D008266:Macula Lutea / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009887:Ophthalmoscopy / Q000379:methods; D017063:Outcome Assessment, Health Care / Q000379:methods; D000069579:Ranibizumab / Q000008:administration & dosage / Q000627:therapeutic use*; D015203:Reproducibility of Results; D055213:Retinal Pigment Epithelium / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D012680:Sensitivity and Specificity; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab